Grant Award Details
- To develop cell-free immunomodulatory therapeutics based on iPSC-EVs and develop a hydrogel delivery platform to enable a prolonged and controlled release of immunomodulatory EVs.
Grant Application Details
- iPSC Extracellular Vesicles for Diabetes Therapy
We will derive extracellular vesicles (EVs) from induced pluripotent stem cells (iPSCs), characterize the content and immunomodulatory activity of EVs, and deliver iPSC-EVs to treat Type-1 diabetes.
Type 1 diabetes (T1D) is an autoimmune disease and there is no therapy to preserve islet cells. Accomplishment of this project will generate a new therapeutic modality for T1D treatment.
Major Proposed Activities
- EV isolation, characterization and reproducibility
- Scaling up EV production in a bioreactor
- Analysis of iPSC EV content and identification of the components for EV quality control
- Development of a hydrogel delivery platform for EV delivery and prolonged presentation
- In vitro assessment of immunomodulatory properties of EVs and development of in vitro functional assay
- Evaluation of safety and immunomodulatory properties of iPSC EVs in vivo in T1D mouse models
Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction of insulin-producing beta cells by patient’s own immune cells. This project aims to develop cell-free immunomodulatory therapeutics based on the extracellular vesicles (EVs) secreted by induced pluripotent stem cells (iPSCs) to treat T1D. This project will develop a new therapeutic modality for the treatment of T1D and autoimmune diseases, and will benefit our citizens and healthcare in California and beyond.